Astrazeneca (AZN) EBT Margin (2009 - 2026)
Astrazeneca (AZN) posted quarterly EBT Margin of 5083.12% for Q1 2026, up 48582.0% year-over-year from N/an in Q1 2025, and down 88.4% on a QoQ basis from 43816.67% in Q4 2025.
Astrazeneca (AZN) EBT Margin (2009 - 2026) Analysis & Trends
Astrazeneca (AZN) has reported EBT Margin for 18 consecutive years, with 5083.12% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 48582.0% year-over-year to 5083.12%; the TTM figure through Mar 2026 stood at 12660.78% (up 1168463.0% YoY), while the FY2025 annual figure was 21.11%, down 92049.0% from the prior year.
- EBT Margin came in at 5083.12% for Q1 2026 at Astrazeneca, down from 43816.67% in the prior quarter.
- The five-year high for EBT Margin was 59925.0% in Q2 2024, with the low at 204.42% in Q4 2024.
- Average EBT Margin over 5 years is 12498.24%, with a median of 4597.3% recorded in 2025.
- Across the five-year window, EBT Margin jumped 5884313 bps in 2024 and plunged 2083750 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 492.41% in 2022, then plunged by 34 bps to 323.83% in 2023, then plunged by 37 bps to 204.42% in 2024, then jumped by 21335 bps to 43816.67% in 2025, then plunged by 88 bps to 5083.12% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 5083.12%, 43816.67%, and 29490.91% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 44.70% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 24.89% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 6.93% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 27.21% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 135.53% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 15.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.21% |
| Dec 31, 2025 | 18.08% |
| Sep 30, 2025 | 22.58% |
| Jun 30, 2025 | 22.67% |
| Mar 31, 2025 | 26.42% |
| Dec 31, 2024 | 12.47% |
| Sep 30, 2024 | 14.12% |
| Jun 30, 2024 | 19.25% |
| Mar 31, 2024 | 22.99% |
| Dec 31, 2023 | 7.92% |
| Sep 30, 2023 | 14.99% |
| Jun 30, 2023 | 19.19% |
| Mar 31, 2023 | 21.41% |
| Dec 31, 2022 | 6.94% |
| Sep 30, 2022 | 8.40% |
| Jun 30, 2022 | 2.32% |
| Mar 31, 2022 | 4.86% |
| Dec 31, 2021 | -5.53% |
| Sep 30, 2021 | -20.54% |
| Jun 30, 2021 | 9.50% |